About Cabling Installation & Maintenance

Our mission: Bringing practical business and technical intelligence to today's structured cabling professionals

For more than 30 years, Cabling Installation & Maintenance has provided useful, practical information to professionals responsible for the specification, design, installation and management of structured cabling systems serving enterprise, data center and other environments. These professionals are challenged to stay informed of constantly evolving standards, system-design and installation approaches, product and system capabilities, technologies, as well as applications that rely on high-performance structured cabling systems. Our editors synthesize these complex issues into multiple information products. This portfolio of information products provides concrete detail that improves the efficiency of day-to-day operations, and equips cabling professionals with the perspective that enables strategic planning for networks’ optimum long-term performance.

Throughout our annual magazine, weekly email newsletters and 24/7/365 website, Cabling Installation & Maintenance digs into the essential topics our audience focuses on.

  • Design, Installation and Testing: We explain the bottom-up design of cabling systems, from case histories of actual projects to solutions for specific problems or aspects of the design process. We also look at specific installations using a case-history approach to highlight challenging problems, solutions and unique features. Additionally, we examine evolving test-and-measurement technologies and techniques designed to address the standards-governed and practical-use performance requirements of cabling systems.
  • Technology: We evaluate product innovations and technology trends as they impact a particular product class through interviews with manufacturers, installers and users, as well as contributed articles from subject-matter experts.
  • Data Center: Cabling Installation & Maintenance takes an in-depth look at design and installation workmanship issues as well as the unique technology being deployed specifically for data centers.
  • Physical Security: Focusing on the areas in which security and IT—and the infrastructure for both—interlock and overlap, we pay specific attention to Internet Protocol’s influence over the development of security applications.
  • Standards: Tracking the activities of North American and international standards-making organizations, we provide updates on specifications that are in-progress, looking forward to how they will affect cabling-system design and installation. We also produce articles explaining the practical aspects of designing and installing cabling systems in accordance with the specifications of established standards.

Cabling Installation & Maintenance is published by Endeavor Business Media, a division of EndeavorB2B.

Contact Cabling Installation & Maintenance

Editorial

Patrick McLaughlin

Serena Aburahma

Advertising and Sponsorship Sales

Peter Fretty - Vice President, Market Leader

Tim Carli - Business Development Manager

Brayden Hudspeth - Sales Development Representative

Subscriptions and Memberships

Subscribe to our newsletters and manage your subscriptions

Feedback/Problems

Send a message to our general in-box

 

Patient Monitoring Stocks Q4 Results: Benchmarking ResMed (NYSE:RMD)

RMD Cover Image

The end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current business environment. Let’s take a look at how ResMed (NYSE: RMD) and the rest of the patient monitoring stocks fared in Q4.

Patient monitoring companies within the healthcare equipment industry offer devices and technologies that track chronic conditions and support real-time health management, such as continuous glucose monitors (CGMs) and sleep apnea machines. These businesses benefit from recurring revenue from consumables and software subscriptions tied to device sales (razor, razor blade model). The rising prevalence of chronic diseases like diabetes and respiratory disorders due to an aging population as well as growing adoption of digitization are good for the industry. However, these companies face challenges from high R&D costs and reliance on regulatory approvals. Looking ahead, the sector is positioned for growth due to tailwinds like the rising burden of chronic diseases from an aging population, the shift toward value-based care, and increased adoption of digital health solutions. Innovations in AI and machine learning are expected to enhance device accuracy and functionality, improving patient outcomes and driving demand. However, there are headwinds such as pricing pressures as healthcare costs are a key focus, especially in the US. An evolving regulatory landscape and competition from more tech-forward new entrants could present additional challenges.

The 5 patient monitoring stocks we track reported a strong Q4. As a group, revenues beat analysts’ consensus estimates by 1.9% while next quarter’s revenue guidance was in line.

Amidst this news, share prices of the companies have had a rough stretch. On average, they are down 11.2% since the latest earnings results.

ResMed (NYSE: RMD)

Founded in 1989 in Australia, ResMed (NYSE: RMD) is a medical device company specializing in products for chronic health conditions like sleep apnea, asthma, neuromuscular disorders, and others.

ResMed reported revenues of $1.28 billion, up 10.3% year on year. This print exceeded analysts’ expectations by 1%. Overall, it was a strong quarter for the company with a narrow beat of analysts’ constant currency revenue estimates and a decent beat of analysts’ EPS estimates.

“Our second quarter fiscal year 2025 top-line growth, margin expansion, and double-digit EPS growth were the result of increased demand for our sleep health and breathing health products and digital health solutions that people love, as well as our laser-focus on operational excellence,” said ResMed’s Chairman and CEO, Mick Farrell.

ResMed Total Revenue

The stock is down 8.4% since reporting and currently trades at $236.01.

We think ResMed is a good business, but is it a buy today? Read our full report here, it’s free.

Best Q4: Masimo (NASDAQ: MASI)

Founded in 1989, Masimo Corporation (NASDAQ: MASI) develops and manufactures medical devices, with a focus on noninvasive monitoring technologies.

Masimo reported revenues of $600.7 million, up 9.4% year on year, outperforming analysts’ expectations by 1.5%. The business had an exceptional quarter with an impressive beat of analysts’ EPS estimates and full-year operating income guidance exceeding analysts’ expectations.

Masimo Total Revenue

Although it had a fine quarter compared to its peers, the market seems unhappy with the results as the stock is down 2.1% since reporting. It currently trades at $165.50.

Is now the time to buy Masimo? Access our full analysis of the earnings results here, it’s free.

Slowest Q4: DexCom (NASDAQ: DXCM)

Founded in 1999 to address the demand for non-invasive diabetes treatments, DexCom (NASDAQ: DXCM) is a medical technology company known for its glucose monitoring systems for people with diabetes.

DexCom reported revenues of $1.11 billion, up 7.6% year on year, exceeding analysts’ expectations by 0.9%. Still, it was a slower quarter as it posted a significant miss of analysts’ EPS estimates.

DexCom delivered the weakest performance against analyst estimates, slowest revenue growth, and weakest full-year guidance update in the group. As expected, the stock is down 15.3% since the results and currently trades at $71.22.

Read our full analysis of DexCom’s results here.

iRhythm (NASDAQ: IRTC)

Founded in 2006, iRhythm Technologies (NASDAQ: IRTC) develops and markets wearable cardiac monitoring devices, focusing on diagnosing and managing heart arrhythmias (irregular heartbeats).

iRhythm reported revenues of $164.3 million, up 24% year on year. This number beat analysts’ expectations by 3.9%. Overall, it was a very strong quarter as it also produced an impressive beat of analysts’ EPS estimates.

iRhythm achieved the biggest analyst estimates beat, fastest revenue growth, and highest full-year guidance raise among its peers. The stock is down 12.8% since reporting and currently trades at $98.01.

Read our full, actionable report on iRhythm here, it’s free.

Insulet (NASDAQ: PODD)

Founded in 2000, Insulet Corporation (NASDAQ: PODD) designs and manufactures insulin delivery systems, with a focus on improving diabetes management through its Omnipod platform.

Insulet reported revenues of $597.5 million, up 17.2% year on year. This result surpassed analysts’ expectations by 2.5%. It was a very strong quarter as it also put up an impressive beat of analysts’ constant currency revenue and EPS estimates.

The stock is down 17.6% since reporting and currently trades at $237.57.

Read our full, actionable report on Insulet here, it’s free.


Want to invest in winners with rock-solid fundamentals? Check out our Strong Momentum Stocks and add them to your watchlist. These companies are poised for growth regardless of the political or macroeconomic climate.

Join Paid Stock Investor Research

Help us make StockStory more helpful to investors like yourself. Join our paid user research session and receive a $50 Amazon gift card for your opinions. Sign up here.

More News

View More

Recent Quotes

View More
Symbol Price Change (%)
AMZN  222.03
+5.55 (2.56%)
AAPL  262.77
+0.53 (0.20%)
AMD  238.03
-2.53 (-1.05%)
BAC  51.52
-0.52 (-1.00%)
GOOG  251.34
-5.68 (-2.21%)
META  733.27
+1.10 (0.15%)
MSFT  517.66
+0.87 (0.17%)
NVDA  181.16
-1.48 (-0.81%)
ORCL  275.15
-2.03 (-0.73%)
TSLA  442.60
-4.83 (-1.08%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.